(Cham: Springer International Publishing), 291327
The Zepbound label carries an identical recommendation for tirzepatide [7]
1 (5th ed.)
Pros Fully licensed and publicly traded, providing a layer of accountability Wide range of treatment categories beyond just weight loss Fast, convenient process for straightforward prescriptions Competitive pricing on many products, especially generics Discreet packaging and home delivery Available in all 50 states Cons Asynchronous consultations may feel impersonal, especially for complex treatments GLP-1 program relies on compounded medications, not brand-name drugs Limited provider continuity
[5] Peptides such as AOD 9604 and retatrutide, when sold with implied therapeutic claims (e.g., fat loss, metabolic enhancement), may legally constitute unlicensed medicinal products, regardless of how they are labelled by suppliers
Oral peptides, small-molecule agonists, and multi-agonist combinations will expand the population that can use incretin-based therapy and will make the class more heterogeneous